Bulletin #6 – March 2022

0

A complete team in place
In recent months Cessatechas part of the progression of our business, have advanced our leadership team, adding important skills within CMC, clinical development, regulatory and commercial to progress and secure the full potential of our key asset CT001

Martin has 14 years of CMC with Lundbeck, Etienne a long history with business development at Leo Pharma and Nycomed, Louise from regulatory consulting and Orphazymeand Benedikte with clinical experience of both Novo Nordisk and Zeeland Pharma
Probably the best small biotech team in the world…

Trial 0204 Results (and Trial 0206 Progress)
In early March, Cessatech announced the positive result of our 0204 bioavailability trial. The primary objective of investigating drug exposure versus IV injection of approved counterparts was successful, and the trial has confirmed the primary endpoint of showing clinically relevant exposure. Additionally, CT001 has been assessed as safe and well tolerated.

Additionally, we have seen very good progress with the 0206 trial (pharmacokinetic trial in children), and we hope to have the last patient visit sometime in April or May. We will announce expected data results once we enroll the last patient. The 0205 pivotal trial is expected to begin in the second quarter, as we are still awaiting ethics committee approval.

Annual Report and Annual General Meeting
The annual report was approved during the GA March 17, 2022Besides Rachel Curtis Gravesen (former communications manager at Genmab for more than 8 years) has been elected to the Board of Directors, and Martin Olin appointed vice-president.

The warrant (incentive) program for key employees and management was continued, and the warrant (share) option was authorized, at a normal share price of DKK0.20 (the same as today 1:1 for shares), but the price of the warrant has yet to be determined (normally an average over a defined period). This should hopefully clear up any misunderstandings.

The journey continues….
We continue to deliver according to our plans, on our very promising asset (CT001), even if the biotech sector has seen headwinds in the stock markets lately. The fundamentals of our business have not changed. Once we have a more stable market, we will slowly increase our investor relations activities.
The year 2022 will be very interesting for the company…

For more information on Cessatechplease contact:
Jes Trygved, CEO
Telephone: +45 9387 2309
Email: [email protected]
www.cessatech.com

On Cessatech
Cessatech A/S is a Danish pharmaceutical company engaged in the development and commercialization of innovative, evidence-based medicines for children for the treatment of acute pediatric pain. Its flagship active ingredient (CT001) is an analgesic nasal spray for the treatment of acute and programmed painful acts in children. Benefits include needle-free administration, easy administration, fast-acting therapeutic effect, and medical approval for children. CT001 is in its pivotal stage of clinical development.

https://news.cision.com/cessatech/r/newsletter–6—mar-2022,c3536544

https://mb.cision.com/Main/19921/3536544/1556993.pdf

(c) Decision 2022. All rights reserved., sources Press Releases – English

Share.

Comments are closed.